ASH-话题@MedSci

#ASH#

242篇内容 | 2147人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1301278, encodeId=823a13012e8fc, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2018 BASHH指南：生殖器支原体感染的管理, objectType=article, longId=175587, objectId=6d7a1e55874e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d7a1e55874e, replyNumber=0, likeNumber=32, createdTime=2019-07-17, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d7a1e55874e, moduleTitle=2018 BASHH指南：生殖器支原体感染的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d7a1e55874e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301277, encodeId=ca3e13012e7f3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2019 ASH临床实践指南：应用促红细胞生成类药物治疗癌症相关贫血, objectType=article, longId=166603, objectId=0666166603fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0666166603fc, replyNumber=0, likeNumber=23, createdTime=2019-05-23, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0666166603fc, moduleTitle=2019 ASH临床实践指南：应用促红细胞生成类药物治疗癌症相关贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0666166603fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301276, encodeId=beaf13012e67a, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=单抗界的板蓝根？继HIV、乳腺癌后 leronlimab向NASH发起挑战！, objectType=article, longId=166153, objectId=4aba16615345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aba16615345, replyNumber=0, likeNumber=64, createdTime=2019-05-17, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aba16615345, moduleTitle=单抗界的板蓝根？继HIV、乳腺癌后 leronlimab向NASH发起挑战！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aba16615345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301275, encodeId=743c13012e52b, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Promethera宣布在2a期临床研究中首次给药，评估世界首例肝干细胞疗法治疗晚期NASH患者, objectType=article, longId=165934, objectId=f5dd165934c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5dd165934c0, replyNumber=0, likeNumber=66, createdTime=2019-05-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5dd165934c0, moduleTitle=Promethera宣布在2a期临床研究中首次给药，评估世界首例肝干细胞疗法治疗晚期NASH患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5dd165934c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301274, encodeId=80ce13012e4bf, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=非酒精性脂肪性肝炎：cilofexor/firsocostat组合在概念验证研究中改善了NASH症状, objectType=article, longId=164168, objectId=8b68164168af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b68164168af, replyNumber=0, likeNumber=42, createdTime=2019-04-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b68164168af, moduleTitle=非酒精性脂肪性肝炎：cilofexor/firsocostat组合在概念验证研究中改善了NASH症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b68164168af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301273, encodeId=586e13012e311, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=JAHA：DASH饮食可降低亚洲人群冠心病和卒中死亡风险, objectType=article, longId=161301, objectId=473f161301de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=473f161301de, replyNumber=0, likeNumber=72, createdTime=2019-03-01, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=473f161301de, moduleTitle=JAHA：DASH饮食可降低亚洲人群冠心病和卒中死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=473f161301de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301272, encodeId=a57e13012e267, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标, objectType=article, longId=160890, objectId=1e4416089059, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4416089059, replyNumber=0, likeNumber=44, createdTime=2019-02-25, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4416089059, moduleTitle=Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4416089059)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301271, encodeId=84d113012e199, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Intercept公司的奥贝胆酸即将成为第一个获批的非酒精性脂肪性肝炎（NASH）药物, objectType=article, longId=160664, objectId=b09616066462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b09616066462, replyNumber=0, likeNumber=76, createdTime=2019-02-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b09616066462, moduleTitle=Intercept公司的奥贝胆酸即将成为第一个获批的非酒精性脂肪性肝炎（NASH）药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b09616066462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301270, encodeId=0def13012e018, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2018ASH进展盘点】邱录贵教授：多发性骨髓瘤基础与临床进展齐飞，中国贡献举足轻重, objectType=article, longId=156831, objectId=56a0156831fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56a0156831fc, replyNumber=0, likeNumber=69, createdTime=2018-12-29, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56a0156831fc, moduleTitle=【2018ASH进展盘点】邱录贵教授：多发性骨髓瘤基础与临床进展齐飞，中国贡献举足轻重, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56a0156831fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301269, encodeId=4dd7130126931, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2018 ASH】侵袭性淋巴瘤领域研究成果丰硕, objectType=article, longId=156703, objectId=832f156e0364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=832f156e0364, replyNumber=0, likeNumber=30, createdTime=2018-12-28, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=832f156e0364, moduleTitle=【2018 ASH】侵袭性淋巴瘤领域研究成果丰硕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=832f156e0364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301268, encodeId=4d991301268d6, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH大会盘点︱周剑峰教授：肿瘤免疫治疗升级，迈入“双靶点”CAR-T时代, objectType=article, longId=155536, objectId=e9fb155536e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9fb155536e6, replyNumber=0, likeNumber=75, createdTime=2018-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9fb155536e6, moduleTitle=ASH大会盘点︱周剑峰教授：肿瘤免疫治疗升级，迈入“双靶点”CAR-T时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9fb155536e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301267, encodeId=acbd130126e8e, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH大会盘点︱邱录贵教授：多发性骨髓瘤靶向新药与免疫治疗新近进展, objectType=article, longId=155535, objectId=1df5155535fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1df5155535fc, replyNumber=0, likeNumber=86, createdTime=2018-12-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1df5155535fc, moduleTitle=ASH大会盘点︱邱录贵教授：多发性骨髓瘤靶向新药与免疫治疗新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1df5155535fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301266, encodeId=fdb01301266dc, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2018 ASH静脉血栓栓塞管理指南：妊娠期间静脉血栓栓塞, objectType=article, longId=155400, objectId=b0b81554007f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0b81554007f, replyNumber=0, likeNumber=28, createdTime=2018-12-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0b81554007f, moduleTitle=2018 ASH静脉血栓栓塞管理指南：妊娠期间静脉血栓栓塞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0b81554007f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301265, encodeId=ec19130126574, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2018 ASH静脉血栓栓塞管理指南：肝素诱导的血小板减少症, objectType=article, longId=155397, objectId=33f315539efb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33f315539efb, replyNumber=0, likeNumber=26, createdTime=2018-12-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33f315539efb, moduleTitle=2018 ASH静脉血栓栓塞管理指南：肝素诱导的血小板减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33f315539efb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301264, encodeId=b4fc130126444, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2018 ASH静脉血栓栓塞管理指南：儿童静脉血栓栓塞症的治疗, objectType=article, longId=155394, objectId=7b7c1553949d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7c1553949d, replyNumber=0, likeNumber=29, createdTime=2018-12-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7c1553949d, moduleTitle=2018 ASH静脉血栓栓塞管理指南：儿童静脉血栓栓塞症的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b7c1553949d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301263, encodeId=9bdf1301263a4, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2018年ASH年会：KTE-X19治疗成人复发难治急性淋巴细胞白血病患者的全新结果, objectType=article, longId=155289, objectId=eab415528991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eab415528991, replyNumber=0, likeNumber=55, createdTime=2018-12-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eab415528991, moduleTitle=2018年ASH年会：KTE-X19治疗成人复发难治急性淋巴细胞白血病患者的全新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eab415528991)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301262, encodeId=3cea1301262cb, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2018年ASH年会：LentiGlobin基因疗法治疗镰刀型红血球疾病的全新数据, objectType=article, longId=155287, objectId=ae7715528ec8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae7715528ec8, replyNumber=0, likeNumber=73, createdTime=2018-12-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae7715528ec8, moduleTitle=2018年ASH年会：LentiGlobin基因疗法治疗镰刀型红血球疾病的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae7715528ec8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301261, encodeId=c317130126163, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2018年ASH年会：CYAD-01治疗恶性血液肿瘤的新近进展, objectType=article, longId=155286, objectId=8dd815528642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd815528642, replyNumber=0, likeNumber=60, createdTime=2018-12-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd815528642, moduleTitle=2018年ASH年会：CYAD-01治疗恶性血液肿瘤的新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dd815528642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301260, encodeId=7c111301260fd, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率, objectType=article, longId=155285, objectId=2ea6155285c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ea6155285c7, replyNumber=0, likeNumber=72, createdTime=2018-12-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ea6155285c7, moduleTitle=2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ea6155285c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301259, encodeId=90a9130125929, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH 2018：创新药临床试验数据汇总, objectType=article, longId=155232, objectId=e9cf15523250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9cf15523250, replyNumber=0, likeNumber=71, createdTime=2018-12-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9cf15523250, moduleTitle=ASH 2018：创新药临床试验数据汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9cf15523250)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASH

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#ASH#

2018 BASHH指南：生殖器支原体感染的管理

2019-07-17

kksonne (审核中...)

前往app查看评论内容

#ASH#

2019 ASH临床实践指南：应用促红细胞生成类药物治疗癌症相关贫血

2019-05-23

kksonne (审核中...)

前往app查看评论内容

#ASH#

单抗界的板蓝根？继HIV、乳腺癌后 leronlimab向NASH发起挑战！

2019-05-17

kksonne (审核中...)

前往app查看评论内容

#ASH#

Promethera宣布在2a期临床研究中首次给药，评估世界首例肝干细胞疗法治疗晚期NASH患者

2019-05-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

非酒精性脂肪性肝炎：cilofexor/firsocostat组合在概念验证研究中改善了NASH症状

2019-04-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

JAHA：DASH饮食可降低亚洲人群冠心病和卒中死亡风险

2019-03-01

kksonne (审核中...)

前往app查看评论内容

#ASH#

Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标

2019-02-25

kksonne (审核中...)

前往app查看评论内容

#ASH#

Intercept公司的奥贝胆酸即将成为第一个获批的非酒精性脂肪性肝炎（NASH）药物

2019-02-22

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2018ASH进展盘点】邱录贵教授：多发性骨髓瘤基础与临床进展齐飞，中国贡献举足轻重

2018-12-29

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2018 ASH】侵袭性淋巴瘤领域研究成果丰硕

2018-12-28

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH大会盘点︱周剑峰教授：肿瘤免疫治疗升级，迈入“双靶点”CAR-T时代

2018-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH大会盘点︱邱录贵教授：多发性骨髓瘤靶向新药与免疫治疗新近进展

2018-12-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

2018 ASH静脉血栓栓塞管理指南：妊娠期间静脉血栓栓塞

2018-12-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

2018 ASH静脉血栓栓塞管理指南：肝素诱导的血小板减少症

2018-12-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

2018 ASH静脉血栓栓塞管理指南：儿童静脉血栓栓塞症的治疗

2018-12-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

2018年ASH年会：KTE-X19治疗成人复发难治急性淋巴细胞白血病患者的全新结果

2018-12-08

kksonne (审核中...)

前往app查看评论内容

#ASH#

2018年ASH年会：LentiGlobin基因疗法治疗镰刀型红血球疾病的全新数据

2018-12-08

kksonne (审核中...)

前往app查看评论内容

#ASH#

2018年ASH年会：CYAD-01治疗恶性血液肿瘤的新近进展

2018-12-08

kksonne (审核中...)

前往app查看评论内容

#ASH#

2018年ASH年会：Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率

2018-12-08

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH 2018：创新药临床试验数据汇总

2018-12-08

科室
- - 订阅+
  - 更多科室
工具
服务